Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996821 | 0.91 | PTGDR2 (0.47) | PTGDR2ALDH1A1RORCNR1I2 | |
| SCHEMBL2351215 | 0.89 | PTGDR2 (0.43) | PTGDR2PPARGPPARAABCC9ABCC8 | |
| SCHEMBL1992682 | 0.89 | PTGDR2 (0.37) | PTGDR2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL1991223 | 0.87 | PTGDR2 (0.52) | PTGDR2PPARGPPARA | |
| SCHEMBL14828506 | 0.84 | PTGDR2 (0.43) | PTGDR2HSD11B1 | |
| SCHEMBL1994155 | 0.79 | PTGDR2 (0.51) | PTGDR2ALDH1A1NR1I2 | |
| SCHEMBL1997126 | 0.78 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL1996728 | 0.78 | PPARG (0.42) | PTGDR2PPARGPPARAABCC9ABCC8 | |
| SCHEMBL1993879 | 0.78 | PTGDR2 (0.44) | PTGDR2NR1I2HSD11B1 | |
| SCHEMBL1988977 | 0.76 | PTGDR2 (0.45) | PTGDR2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8008350-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885ALDH1A1 224/4885RORC 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.